Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1998 Aug;65(2):213–217. doi: 10.1136/jnnp.65.2.213

Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome

P Maddison 1, J Newsom-Davis 1, K Mills 1
PMCID: PMC2170198  PMID: 9703174

Abstract

OBJECTIVE—To assess the distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome (LEMS) to identify the most sensitive muscle to use in routine examination.
METHODS—Surface recorded compound muscle action potential (CMAP) amplitudes were made from abductor digiti minimi, abductor pollicis brevis, anconeus, biceps brachii, and trapezius in 10 patients with LEMS. The effect of 3,4-diaminopyridine (3,4-DAP) was recorded in each muscle in nine patients. CMAP amplitudes were measured at rest and immediately after 10 seconds maximal voluntary contraction in each muscle. Values were compared with results obtained from 12 healthy controls.
RESULTS—Resting CMAP amplitudes were reduced in at least one muscle in all patients compared with controls, most markedly in abductor digiti minimi and anconeus. The administration of 3,4-DAP resulted in significantly improved resting CMAP amplitudes in trapezius only. After maximal voluntary muscle contraction, characteristic increments in CMAP amplitude of over 100% above resting values were seen in abductor digiti minimi and abductor pollicis brevis in seven patients, anconeus and biceps brachii in five patients. No patient had this level of increment in trapezius.
CONCLUSION—Despite predominantly proximal limb weakness seen clinically in patients with LEMS, the most sensitive muscles for detecting characteristic electrophysiological abnormalities of low resting CMAP amplitude and increment of over 100% after 10 seconds maximal voluntary contraction are abductor digiti minimi, abductor pollicis brevis, and anconeus.



Full Text

The Full Text of this article is available as a PDF (141.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Howard J. F., Jr, Sanders D. B., Massey J. M. The electrodiagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Neurol Clin. 1994 May;12(2):305–330. [PubMed] [Google Scholar]
  2. Ingram D. A., Davis G. R., Schwartz M. S., Traub M., Newland A. C., Swash M. Cancer-associated myasthenic (Eaton-Lambert) syndrome: distribution of abnormality and effect of treatment. J Neurol Neurosurg Psychiatry. 1984 Aug;47(8):806–812. doi: 10.1136/jnnp.47.8.806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kennett R. P., Fawcett P. R. Repetitive nerve stimulation of anconeus in the assessment of neuromuscular transmission disorders. Electroencephalogr Clin Neurophysiol. 1993 Jun;89(3):170–176. doi: 10.1016/0168-5597(93)90130-h. [DOI] [PubMed] [Google Scholar]
  4. Lambert E. H., Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann N Y Acad Sci. 1971 Sep 15;183:183–199. doi: 10.1111/j.1749-6632.1971.tb30750.x. [DOI] [PubMed] [Google Scholar]
  5. Lang B., Newsom-Davis J., Wray D., Vincent A., Murray N. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet. 1981 Aug 1;2(8240):224–226. doi: 10.1016/s0140-6736(81)90474-8. [DOI] [PubMed] [Google Scholar]
  6. Lennon V. A., Kryzer T. J., Griesmann G. E., O'Suilleabhain P. E., Windebank A. J., Woppmann A., Miljanich G. P., Lambert E. H. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995 Jun 1;332(22):1467–1474. doi: 10.1056/NEJM199506013322203. [DOI] [PubMed] [Google Scholar]
  7. Lundh H., Nilsson O., Rosén I., Johansson S. Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol Scand. 1993 Aug;88(2):136–140. doi: 10.1111/j.1600-0404.1993.tb04205.x. [DOI] [PubMed] [Google Scholar]
  8. Lundh H., Nilsson O., Rosén I. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology. 1984 Oct;34(10):1324–1330. doi: 10.1212/wnl.34.10.1324. [DOI] [PubMed] [Google Scholar]
  9. McEvoy K. M., Windebank A. J., Daube J. R., Low P. A. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med. 1989 Dec 7;321(23):1567–1571. doi: 10.1056/NEJM198912073212303. [DOI] [PubMed] [Google Scholar]
  10. Motomura M., Johnston I., Lang B., Vincent A., Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 1995 Jan;58(1):85–87. doi: 10.1136/jnnp.58.1.85. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Murray N. M., Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology. 1981 Mar;31(3):265–271. doi: 10.1212/wnl.31.3.265. [DOI] [PubMed] [Google Scholar]
  12. Newsom-Davis J., Murray N. M. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology. 1984 Apr;34(4):480–485. doi: 10.1212/wnl.34.4.480. [DOI] [PubMed] [Google Scholar]
  13. O'Neill J. H., Murray N. M., Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988 Jun;111(Pt 3):577–596. doi: 10.1093/brain/111.3.577. [DOI] [PubMed] [Google Scholar]
  14. Oh S. J. Diverse electrophysiological spectrum of the Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1989 Jun;12(6):464–469. doi: 10.1002/mus.880120605. [DOI] [PubMed] [Google Scholar]
  15. Oh S. J., Head T., Fesenmeier J., Claussen G. Peroneal nerve repetitive nerve stimulation test: its value in diagnosis of myasthenia gravis and Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1995 Aug;18(8):867–873. doi: 10.1002/mus.880180811. [DOI] [PubMed] [Google Scholar]
  16. Oh S. J., Kim D. E., Kuruoglu R., Brooks J., Claussen G. Electrophysiological and clinical correlations in the Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1996 Jul;19(7):903–906. doi: 10.1002/(SICI)1097-4598(199607)19:7<903::AID-MUS15>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  17. Ozdemir C., Young R. R. The results to be expected from electrical testing in the diagnosis of myasthenia gravis. Ann N Y Acad Sci. 1976;274:203–222. doi: 10.1111/j.1749-6632.1976.tb47686.x. [DOI] [PubMed] [Google Scholar]
  18. Sanders D. B. Clinical neurophysiology of disorders of the neuromuscular junction. J Clin Neurophysiol. 1993 Apr;10(2):167–180. doi: 10.1097/00004691-199304000-00004. [DOI] [PubMed] [Google Scholar]
  19. Sanders D. B. The effect of firing rate on neuromuscular jitter in Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1992 Feb;15(2):256–258. [PubMed] [Google Scholar]
  20. Schumm F., Stöhr M. Accessory nerve stimulation in the assessment of myasthenia gravis. Muscle Nerve. 1984 Feb;7(2):147–151. doi: 10.1002/mus.880070211. [DOI] [PubMed] [Google Scholar]
  21. Stalberg E. Clinical electrophysiology in myasthenia gravis. J Neurol Neurosurg Psychiatry. 1980 Jul;43(7):622–633. doi: 10.1136/jnnp.43.7.622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Tim R. W., Sanders D. B. Repetitive nerve stimulation studies in the Lambert-Eaton myasthenic syndrome. Muscle Nerve. 1994 Sep;17(9):995–1001. doi: 10.1002/mus.880170906. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES